Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixido-Tura, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., De Backer, J., Deglise, S., Della Corte, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 993
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Self-citationJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., Post, W. S., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 658
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
“[201] The ASCEND Study Collaborative Group, “Effects of aspirin”
BackgroundMethodZheng, S. L., & Roddick, A. J. (2019) · JAMA · doi:10.1001/jama.2018.20578 · Cited by 577
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., Oliveira, G. M. M. D., Simão, A. F., Dutra, O. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R. M. D. S., Giuliano, I. D. C. B., Alencar Filho, A. C. D., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 434
Koo, B.-K., Kang, J., Park, K. W., Rhee, T.-M., Yang, H.-M., Won, K.-B., Rha, S.-W., Bae, J.-W., Lee, N. H., Hur, S.-H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01063-1 · Cited by 370
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease
Liberale, L., Montecucco, F., Tardif, J.-C., Libby, P., & Camici, G. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz961 · Cited by 345
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
Cho, L., Davis, M., Elgendy, I., Epps, K., Lindley, K. J., Mehta, P. K., Michos, E. D., Minissian, M., Pepine, C., Vaccarino, V., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.060 · Cited by 347
The first 3500 years of aspirin history from its roots – A concise summary
Montinari, M. R., Minelli, S., & De Caterina, R. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2018.10.008 · Cited by 315
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
Jones, W. S., Mulder, H., Wruck, L. M., Pencina, M. J., Kripalani, S., Muñoz, D., Crenshaw, D. L., Effron, M. B., Re, R. N., Gupta, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102137 · Cited by 307
Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041998 · Cited by 301
Sharifi-Rad, J., Rodrigues, C. F., Sharopov, F., Docea, A. O., Can Karaca, A., Sharifi-Rad, M., Kahveci Karıncaoglu, D., Gülseren, G., Şenol, E., Demircan, E., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072326 · Cited by 285
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
2024 Clinical practice guidelines for Hypertension in adults
Kobalava, Z. D., Konradi, A. O., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Baranova, E. I., Barbarash, O. L., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 211
Evidence-Based Medical Management of Peripheral Artery Disease
Bevan, G. H., & White Solaru, K. T. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312142 · Cited by 211
Cainzos-Achirica, M., Miedema, M. D., McEvoy, J. W., Al Rifai, M., Greenland, P., Dardari, Z., Budoff, M., Blumenthal, R. S., Yeboah, J., Duprez, D. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.045010 · Cited by 201
Vulnerable plaques and patients: state-of-the-art
Tomaniak, M., Katagiri, Y., Modolo, R., de Silva, R., Khamis, R. Y., Bourantas, C. V., Torii, R., Wentzel, J. J., Gijsen, F. J. H., van Soest, G., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa227 · Cited by 197
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
Hodis, H. N., & Mack, W. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000591 · Cited by 187
Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis
Li, X., Weber, N. C., Cohn, D. M., Hollmann, M. W., DeVries, J. H., Hermanides, J., & Preckel, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112419 · Cited by 181
“Due to the prothrombotic state and enhanced cardiovascular risk in diabetic patients, the necessity of antiplatelet and anticoagulation therapy is well acknowledged, but the optimal treatment strategies remain controversial [78,79].”
BackgroundMehta, L. S., Velarde, G. P., Lewey, J., Sharma, G., Bond, R. M., Navas-Acien, A., Fretts, A. M., Magwood, G. S., Yang, E., Blumenthal, R. S., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001139 · Cited by 181
Lordan, R., Tsoupras, A., & Zabetakis, I. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100694 · Cited by 179
The rise and fall of aspirin in the primary prevention of cardiovascular disease
Raber, I., McCarthy, C. P., Vaduganathan, M., Bhatt, D. L., Wood, D. A., Cleland, J. G. F., Blumenthal, R. S., & McEvoy, J. W. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30541-0 · Cited by 177
Mahmoud, A. N., Gad, M. M., Elgendy, A. Y., Elgendy, I. Y., & Bavry, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy813 · Cited by 176
“One argument might be to consider using aspirin for reducing the risk of cancer,(29) again this evidence was based mainly on old trials and has not been replicated in the more recent trials.(13,30) Further, this meta-analysis found no evidence of reduction in allcause mortality, thus disputing any potential mortality…”
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“However, these preventive benefits were counterbalanced with major bleeding hazards.[560] Furthermore, a metaanalysis demonstrated 35% reduction in MI among men (RR: 0.”
BackgroundHastie, R., Tong, S., Wikström, A.-K., Sandström, A., Hesselman, S., & Bergman, L. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.07.023 · Cited by 165
Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
Siegel, K. R., Ali, M. K., Zhou, X., Ng, B. P., Jawanda, S., Proia, K., Zhang, X., Gregg, E. W., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0017 · Cited by 164
Guirguis-Blake, J. M., Evans, C. V., Perdue, L. A., Bean, S. I., & Senger, C. A. (2022) · JAMA · doi:10.1001/jama.2022.3337 · Cited by 163
Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046448 · Cited by 158
Role of aspirin in primary prevention of cardiovascular disease
Patrono, C., & Baigent, C. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0225-y · Cited by 172
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
McNeil, J. J., Gibbs, P., Orchard, S. G., Lockery, J. E., Bernstein, W. B., Cao, Y., Ford, L. G., Haydon, A. M., Kirpach, B., Macrae, F., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa114 · Cited by 167
“4 years of follow-up.(24) However the most recently published meta-analysis by Rothwell et al.”
BackgroundSelf-citationOlivera, P. A., Zuily, S., Kotze, P. G., Regnault, V., Awadhi, S. A., Bossuyt, P. J., Gearry, R. B., Ghosh, S. K., Kobayashi, T., Lacolley, P. J., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00492-8 · Cited by 175
Cardiovascular Risk in Type 1 Diabetes Mellitus
Schofield, J. D., Ho, J. H., & Soran, H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0612-8 · Cited by 177
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 192
(2022) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezag193 · Cited by 184
Inflammation and cardiovascular diseases: lessons from seminal clinical trials
Liberale, L., Montecucco, F., Schwarz, L., Lüscher, T. F., & Camici, G. G. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa211 · Cited by 160
Aspirin for Primary Prevention of Cardiovascular Events
Abdelaziz, H. K., Saad, M. S., Pothineni, N. V. K., Megaly, M. S., Potluri, R., Saleh, M. A. D., Kon, D. L. C., Roberts, D. H., Bhatt, D. L., Aronow, H. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.501 · Cited by 155
“Four RCTs enrolled only diabetic patients (13,19,21,30), whereas 1 excluded this population (20).”
BackgroundInfluentialDrapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 231
Ten things to know about ten cardiovascular disease risk factors – 2022
Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 170
Current concepts and novel targets for antiplatelet therapy
Gawaz, M., Geisler, T., & Borst, O. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00854-6 · Cited by 148
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 136
Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions
Zhao, L., Hu, H., Zhang, L., Liu, Z., Huang, Y., Liu, Q., Jin, L., Zhu, M., & Zhang, L. (2024) · MedComm · doi:10.1002/mco2.516 · Cited by 146
“226 For example, salsalate, one of NSAIDs, could reduce inflammatory parameters such as CRP, free fatty acid in obese individuals at high risk of DM. 225 Anti-inflammatory effect of salsalate could improve blood glucose parameters and insulin sensitivity.”
BackgroundCapodanno, D., Bhatt, D. L., Eikelboom, J. W., Fox, K. A. A., Geisler, T., Gibson, C. M., González‐Juanatey, J. R., James, S. K., Lópes, R. D., Mehran, R., et al. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0314-y · Cited by 127
Aspirin and antiplatelet treatments in cancer
Tao, D. L., Yunga, S. T., Williams, C. D., & McCarty, O. J. T. (2021) · Blood · doi:10.1182/blood.2019003977 · Cited by 133
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 128
Indian guidelines on hypertension-IV (2019)
Shah, S. N., Munjal, Y. P., Kamath, S. A., Wander, G. S., Mehta, N., Mukherjee, S., Kirpalani, A. L., Gupta, P., Shah, H., Rohatgi, R., et al. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0349-x · Cited by 127
Ajufo, E. C., Ayers, C. R., Vigen, R., Joshi, P. H., Rohatgi, A. K., de Lemos, J. A., & Khera, A. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4939 · Cited by 126
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 132
Gelbenegger, G., Postula, M. A., Pecen, L., Halvorsen, S., Lesiak, M., Schoergenhofer, C., Jilma, B., Hengstenberg, C., & Siller-Matula, J. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1428-0 · Cited by 113
“Only the ASCEND trial [18] showed a significant reduction in the rate of major adverse CV events, but the effect was, once again, accompanied by a significant increase in major bleeding.”
BackgroundInfluentialO'Brien, C. W., Juraschek, S. P., & Wee, C. C. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0953 · Cited by 100
Williams, M. C., Wereski, R., Tuck, C. E., Adamson, P. D., Shah, A. S. V., van Beek, E. J. R., Roditi, G., Berry, C., Boon, N. A., Flather, M., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02679-5 · Cited by 108
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
Patrono, C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae324 · Cited by 114
“…recent placebo-controlled RCTs for primary prevention, ASCEND, is of the same order of magnitude as the absolute reduction in major vascular events, 60 confirming a substantially uncertain balance of benefits and risks, 61 as previously reported by an IPD meta-analysis of the six earliest primary…”
ResultMeasurement of Thromboxane Biosynthesis in Health and Disease
Patrono, C., & Rocca, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01244 · Cited by 113
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 117
A systematic review of methods used to conduct decentralised clinical trials
Rogers, A., Paoli, G. D., Subbarayan, S., Copland, R. R., Harwood, K. E., Coyle, J., Mitchell, L., MacDonald, T. M., & Mackenzie, I. S. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15205 · Cited by 98
Ernst, M. E., Broder, J. C., Wolfe, R. S., Woods, R. L., Nelson, M. R., Ryan, J. L., Shah, R. C., Orchard, S. G., Chan, A. T., Espinoza, S. E., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107231 · Cited by 96
Platelets as therapeutic targets to prevent atherosclerosis
Nording, H., Baron, L., & Langer, H. F. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.05.018 · Cited by 91
Should Aspirin Be Used for Primary Prevention in the Post-Statin Era?
Ridker, P. M. (2018) · New England Journal of Medicine · doi:10.1056/nejme1812000 · Cited by 92
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 101
Marquis‐Gravel, G., Roe, M. T., Robertson, H. R., Harrington, R. A., Pencina, M. J., Berdan, L. G., Hammill, B. G., Modrow, M. F., Muñoz, D., Fonarow, G. C., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0116 · Cited by 89
Bhatia, H. S., Trainor, P. J., Carlisle, S. M., Tsai, M. Y., Criqui, M. H., DeFilippis, A. P., & Tsimikas, S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033562 · Cited by 103
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Antonopoulos, A. S., Angelopoulos, A., Tsioufis, K. P., Antoniades, C. A., & Tousoulis, D. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab067 · Cited by 97
The importance of long-term follow up of participants in clinical trials
Cuzick, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02038-4 · Cited by 101
“A current challenge for understanding the role of aspirin for cancer prevention comes from the results of two recent reports on studies with short follow up [52, 53].”
ResultLin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review
Szczuko, M., Kozioł, I., Kotlęga, D., Brodowski, J., & Drozd, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111644 · Cited by 87
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 121
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
Khan, A. W., & Jandeleit-Dahm, K. A. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01115-w · Cited by 95
“The ASCEND trial 132 in individuals with diabetes without known atherosclerotic CVD showed that the benefit of aspirin in preventing serious vascular events was counterbalanced by an increased risk of major bleeding.”
Huang, W., Saver, J. L., Wu, Y., Lin, C., Lee, M., & Ovbiagele, B. I. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1120 · Cited by 83
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Majithia, A., & Bhatt, D. L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310955 · Cited by 82
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Mortensen, M. B., & Nordestgaard, B. G. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3665 · Cited by 86
Ciliberti, G., Verdoia, M., Merlo, M., Zilio, F., Vatrano, M., Bianco, F., Mancone, M., Zaffalon, D., Bonci, A., Boscutti, A., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.040 · Cited by 73
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.